Ocugen Gets FDA RMAT Designation
Ocugen receives RMAT designation for OCU410
Story updates
11:53:45 AM UTC
SquawkNews
OCGN Ocugen announces that the U.S. food and drug administration has granted ocu410 regenerative Medicine advanced therapy (rmat) designation for treatment of geographic atrophy, secondary to dry age-related macular degeneration Ocugen - to initiate ocu410 phase 3 trial in Q3 2026, BLA filing anticipated in 2028
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.